Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $36.33 Analyst target: $72.56 Upside: 99.72%
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.